We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Approves Ranbaxy's Generic Claritin

FDA Approves Ranbaxy's Generic Claritin

April 13, 2007

Ohm Laboratories, a wholly owned subsidiary of Ranbaxy Laboratories, announced it has received FDA approval to manufacture and commercialize its generic loratadine orally disintegrating tablets, 10 mg.

The FDA's Division of Bioequivalence has determined the product to be bioequivalent to the reference-listed drug, Schering-Plough's Claritin Reditabs, a long-acting antihistamine agent that has annual sales of $58.7 million, Ranbaxy said.

Loratadine is indicated for the temporary relief of runny nose, sneezing, itching of the nose or throat, itchy watery eyes due to hay fever or other respiratory allergies in adults and children 6 and older, according to Ranbaxy.

"With Loratadine, Ohm will be launching another OTC product offering that represents a molecule with value and utility, marketed in the private label or store brand segment of the U.S. healthcare system," Robert Haywood, senior director of OTC sales and marketing at Ohm, said.

Ranbaxy also announced recently that has received Health Canada approval to manufacture and market RAN-Cefprozil tablets, 250 and 500 mg, and RAN-Cefprozil powder for oral suspension, 250 mg/5 mL.

Cefprozil is indicated for the treatment of upper respiratory tract infections, uncomplicated skin infections and urinary tract infections, according to Ranbaxy.

KEYWORDS Drug Pipeline Alert

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

  • FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

  • FDA Expands Approval for Merck’s Keytruda in NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing